Svein Lien appointed new CEO of Biotec Pharmacon ASA
Published 10.03.2010
Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 1...
Biotec Pharmacon presenting re-established platform at BIO-Europe 2010
Published 09.03.2010
Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Se...
Testing SBG packaging containers after weak results from oral mucositis study
Published 22.02.2010
Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays in...
Biotec Pharmacon to focus on bio-pharmaceuticals - sells Immunocorp Consumer Health AS
Published 30.12.2009
Biotec Pharmacon ASA has reached an agreement on the sale of its wholly-owned subsidiaries Immunocorp Consumer Health AS and Immunocorp Inc. USA to the Norwegian company Sana Pharm...
Biotec Pharmacon realigns strategy and reduces workforce
Published 11.12.2009
Biotec Pharmacon has decided to reduce the workforce within the parent company by 20 people out of a total of 35, to reflect a reduced activity level following the negative outcome...
Phase III results with SBG for diabetic foot ulcer not positive
Published 23.11.2009
Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies fail...
Databases locked in both the phase III clinical studies with SBG for diabetic foot ulcer
Published 03.11.2009
Biotec Pharmacon is pleased to inform that all data management procedures have been completed, and that the databases have been locked in both of the company’s phase III studies wi...
Presenting at Bio Investor Forum in San Francisco and at Bio Europe 2009 in Vienna
Published 28.10.2009
Biotec Pharmacon has been invited to present at the 8th Annual Bio Investor Forum in San Francisco on October 28th and at BIO-Europe 2009 Conference in Vienna on November 3rd, 2009...
